Noteworthy Wednesday Option Activity: FHN, UTHR, SLAB

United Therapeutics (UTHR) saw unusually high options activity with 5,828 contracts traded (≈582,800 underlying shares), equal to ~177.7% of its one‑month average daily volume (327,980 shares); the April 17, 2026 $530 call accounted for 1,910 contracts (~191,000 shares). Silicon Laboratories (SLAB) recorded 6,041 option contracts (≈604,100 underlying shares), ~173.8% of its one‑month average daily volume (347,620 shares), led by 2,460 contracts in the Feb 20, 2026 $200 put (~246,000 shares). The volumes suggest concentrated speculative or hedging flows that could influence intraday liquidity and price moves in both names.

Analysis

Market structure: The concentrated activity (UTHR Apr‑17‑2026 $530 calls = 1,910 contracts ≈191k shares; SLAB Feb‑20‑2026 $200 puts = 2,460 contracts ≈246k shares) implies institutional directional or hedging flow that will force dealer delta/vega hedging into the cash market. Winners: option buyers and any liquidity providers who can monetize elevated IV; losers: passive long holders in SLAB if puts represent fresh downside conviction, and short-dated volatility sellers. The immediate supply/demand imbalance in listed options will lift implied vol and can mechanically move underlying via gamma-hedging over the next days/weeks.

Risk assessment: Tail risks include an adverse FDA decision or trial update for UTHR (binary shock) and a semiconductor capex slowdown or large inventory write‑down for SLAB; both could move >20–40% on event days. Time horizons: expect gamma-driven moves in days–weeks around trade prints, IV re-pricing over months (to expiries Feb/Apr 2026), and fundamental reversion over quarters. Hidden dependencies: trades may be parts of multi-legged structures (collars, index hedges) or blocks tied to corporate activity; monitor block trade prints and 13F changes. Catalysts: upcoming earnings, FDA calendar for UTHR, and semi capex indicators (TSMC guidance, PMI) in the next 30–90 days.

Trade implications: Direct: Establish a defined‑risk directional exposure rather than naked options. For UTHR consider a small (1–2% portfolio) long via Apr‑17‑2026 520/560 call spread to capture upside while limiting premium; for SLAB buy a Feb‑20‑2026 200/160 put spread (1–2%) or a collar if you hold stock. Pair: long UTHR call spread vs short SLAB equity (or short SLAB Jan‑Feb 2026 call overwrites) to play flow divergence. Entry: initiate within 5 trading days; trim at +30% or if IV rises >20% from entry.

Contrarian angles: The obvious read (bullish UTHR, bearish SLAB) may be overstated — heavy put volume often signals hedging of long equity positions, not fresh bearish conviction, and large call blocks can be long‑dated hedges or covered call sellers. Historical parallels show large option prints often precede short-term momentum that fades once dealer hedges exhaust (look for reversion 2–6 weeks post‑print). Unintended consequence: crowded directional option trades can produce violent whipsaws; set stop thresholds (close if underlying moves ±15% in 10 trading days or IV moves >25%).

Key Decisions for Investors

• Establish a 1–2% position in UTHR via a defined‑risk Apr‑17‑2026 520/560 call spread (buy 520, sell 560) within 5 trading days to capture potential upside signaled by heavy $530 call flow; cap downside premium and target a +30% profit or unwind if IV rises >20%.
• Reduce net cyclicals exposure by 1–3% and initiate a protective SLAB trade: buy Feb‑20‑2026 200/160 put spread sized to cover 1–2% portfolio risk (or equivalent collar) to hedge against semiconductor capex downside ahead of next two quarters of guidance releases.
• Implement a relative‑value pair: long UTHR call‑spread (as above) and short 0.5–1.0% SLAB equity (or short-term calls) to monetize divergent option flows; rebalance if spread P/L moves ±25% or if either stock moves >15% in 10 trading days.
• Monitor three actionable triggers over the next 30–90 days: (1) UTHR FDA/trial calendar and earnings dates, (2) SLAB/semicap guidance and PMIs, (3) option IV moves — unwind directional option exposure if IV increases >25% or if underlying gaps beyond ±15% intraday.